21,593 Shares in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Bought by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC purchased a new stake in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 21,593 shares of the company’s stock, valued at approximately $187,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Gladius Capital Management LP purchased a new stake in shares of Maravai LifeSciences during the 4th quarter valued at about $30,000. Performa Ltd US LLC lifted its position in shares of Maravai LifeSciences by 112.4% during the fourth quarter. Performa Ltd US LLC now owns 6,000 shares of the company’s stock worth $39,000 after purchasing an additional 3,175 shares in the last quarter. Pinnacle Associates Ltd. purchased a new position in shares of Maravai LifeSciences in the fourth quarter valued at $69,000. Sherbrooke Park Advisers LLC acquired a new stake in Maravai LifeSciences during the 3rd quarter valued at $143,000. Finally, Burgundy Asset Management Ltd. purchased a new stake in Maravai LifeSciences during the 4th quarter worth $95,000. 50.25% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Gtcr Investment Xi Llc sold 9,940,974 shares of the firm’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $9.81, for a total value of $97,520,954.94. Following the sale, the director now owns 20,150,005 shares of the company’s stock, valued at approximately $197,671,549.05. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 0.63% of the company’s stock.

Maravai LifeSciences Stock Performance

MRVI stock opened at $7.08 on Friday. The firm has a market cap of $1.78 billion, a P/E ratio of -7.15 and a beta of 0.06. The stock’s 50 day simple moving average is $8.77 and its 200 day simple moving average is $7.56. The company has a current ratio of 11.32, a quick ratio of 10.47 and a debt-to-equity ratio of 0.71. Maravai LifeSciences Holdings, Inc. has a 12-month low of $4.52 and a 12-month high of $13.31.

Maravai LifeSciences (NASDAQ:MRVI) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.05). Maravai LifeSciences had a negative return on equity of 4.28% and a negative net margin of 47.81%. The business had revenue of $64.18 million during the quarter, compared to the consensus estimate of $60.84 million. As a group, equities research analysts predict that Maravai LifeSciences Holdings, Inc. will post -0.15 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on MRVI shares. Robert W. Baird raised their target price on Maravai LifeSciences from $8.00 to $10.00 and gave the company an “outperform” rating in a research note on Thursday, May 9th. Craig Hallum began coverage on Maravai LifeSciences in a research note on Wednesday, April 10th. They set a “buy” rating and a $15.00 price objective for the company. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $11.44.

Maravai LifeSciences Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.